Novartis Targeting India For Natural Drug Ingredients
This article was originally published in PharmAsia News
Executive Summary
India is a prime target for Novartis, the Swiss drug maker looking for biodiverse resources from which to produce drugs. The outgoing chairman of Novartis India said the parent company is looking at the seas, rain forests, fungi and micro-organisms that use natural ingredients to protect themselves. Peter Jager said a Novartis project in China is looking at fungi that contain an ingredient that fights cancer, and at a micro-organism in Thailand that grows on an insect. But Jager said India itself has a great potential for bioresources and is part of the Novartis research plan. (Click here for more
You may also be interested in...
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.